Abeona Therapeutics Inc. (Nasdaq: ABEO) has announced its financial results for the year ended December 31, 2025, highlighting significant operational progress and a positive outlook for its gene therapy product, ZEVASKYN. The company reported total revenues of $5.8 million, which included $2.4 million in net product revenue from a single patient treatment completed in December 2025. This marks a pivotal moment for Abeona as it transitions into a commercial-stage biopharmaceutical company. The company also reported a net income of $71.2 million for the year, a substantial turnaround from a net loss of $63.7 million in 2024. This improvement was largely driven by the sale of a Rare Pediatric Disease Priority Review Voucher, which generated $155 million in gross proceeds. Abeona's cash, cash equivalents, and short-term investments totaled $191.4 million as of December 31, 2025, providing a solid financial foundation for future growth. CEO Vish Seshadri emphasized the company's commitment to ensuring a seamless treatment experience for ZEVASKYN patients and building a steady cadence of treatments in 2026. The company is focused on expanding patient access and establishing a scalable foundation for ZEVASKYN, which is the first and only autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). With the recent activation of new Qualified Treatment Centers, Abeona is poised to accelerate patient throughput and streamline the referral-to-treatment timeline. The company will host a conference call on March 17, 2026, to discuss its financial results and corporate progress further.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.